TECH — BIO-TECHNE Corp
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 842023 ·
Last close
$72.61
Market Cap
$11.39B
52W High
$72.69
52W Low
$43.07
ADV30
2,760,893
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | — | — | — | — |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 295,877,000 | 191,277,000 | 54,461,000 | 38,009,000 | 2,522,699,000 | 172,879,000 | 511,710,000 |
| Sep 2025 | 286,555,000 | 188,112,000 | 47,658,000 | 38,185,000 | 2,526,148,000 | 144,962,000 | 560,334,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$294,858,000
Investing CF
$-10,727,000
Financing CF
$-226,358,000
CapEx
$-25,260,000
Dividends Paid
$-49,819,000
Buybacks
$-100,081,000
EPS Diluted TTM
$0.69
As of
2026-08-30
Balance + Analyst (yfinance extras)
Retained Earnings
$1,145,192,000
Inventory
$201,175,000
Receivables
$214,562,000
ST Investments
$0
EBIT TTM
$156,826,000
Pretax Income TTM
$147,141,000
Interest Exp TTM
$9,685,000
Analysts
11
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,215,038,976
EBITDA
$334,105,984
Free Cash Flow
$229,653,120
Enterprise Value
$11,333,339,136
Total Cash
$265,479,008
Total Debt
$289,087,008
Shares Out
156,818,238
Trailing EPS
$1.16
Book Value
$13.51
ROE
9.0%
ROA
6.7%
Div Yield
0.44%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 1,215,039,000 | 272,611,000 | 181,862,000 | 2,586,726,000 | 478,505,000 | 2,108,221,000 | 292,073,000 |
| Jun 2025 | 1,219,635,000 | 242,804,000 | 73,400,000 | 2,557,868,000 | 639,060,000 | 1,918,808,000 | 287,556,000 |
| Jun 2024 | 1,159,060,000 | 246,401,000 | 168,105,000 | 2,703,867,000 | 635,017,000 | 2,068,850,000 | 298,981,000 |
| Jun 2023 | 1,136,702,000 | 290,998,000 | 285,263,000 | 2,638,692,000 | 672,176,000 | 1,966,516,000 | 254,393,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$2.31
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $60.00 · spot: $72.61 · call volume: 2,076 · put volume: 16Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RGEN | REPLIGEN CORP | $10.70B | $189.68 | — |
| TWST | Twist Bioscience Corp | $12.12B | $182.83 | — |
| KRYS | Krystal Biotech, Inc. | $10.24B | $345.82 | — |
| HALO | HALOZYME THERAPEUTICS, INC. | $12.93B | $113.90 | — |
| NBIX | NEUROCRINE BIOSCIENCES INC | $14.07B | $138.40 | — |
News headlines (Yahoo Finance, 1h cache)
Bio-Techne Shareholders Approve Acquisition by Merck KGaA, Darmstadt, Germany
2026-09-23 13:20 · Yahoo
Bio-Techne Opens New Customer Experience Center in Düsseldorf to Accelerate Scientific Discovery and Customer Collaboration
2026-09-22 13:00 · Yahoo
Bio Techne (TECH) And The Valuation Case Behind Its Recent Rebound
2026-09-15 04:30 · Yahoo
Bio-Techne Achieves Science Based Targets Validation and Reports Significant Progress Toward Climate Goals
2026-09-01 10:30 · Yahoo
Winners And Losers Of Q2: Bio-Techne (NASDAQ:TECH) Vs The Rest Of The Research Tools & Consumables Stocks
2026-08-31 21:08 · Yahoo
Bio-Techne Corrects Dividend Announcement
2026-08-13 10:30 · Yahoo
Bio-Techne (NASDAQ:TECH) Surprises With Q2 CY2026 Sales
2026-08-12 11:37 · Yahoo
Is Bio-Techne Stock Outperforming the Nasdaq?
2026-09-24 08:47 · Yahoo
Bio-Techne (TECH) Shareholders Approve the Merck KGaA Takeover and Reject the Pay Package
2026-09-26 03:57 · Yahoo
3 Reasons to Sell TECH and 1 Stock to Buy Instead
2026-09-23 13:41 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.